A putative sirolimus (rapamycin) effector protein

59Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Sirolimus (rapamycin), a new immunosuppressive drug, inhibits proliferation of a wide spectrum of T and B cells. The immunosuppressive mechanism of sirolimus is still unclear. We recently isolated a membrane associated protein with an apparent molecular weight of 210 kDa, p210, from cultured Molt 4 cells and BJAB cells and from normal human T cells using an affinity matrix method. The p210 binds to sirolimus:FKBP12 complex, but only at background levels to FKBP12 alone, to FK506:FKBP12 complex, or sirolimus-biotin alone. Among the sirolimus analogs tested, the binding ability of p210 to drug:FKBP12 complexes correlates with the immunosuppressive activity of the drugs, suggesting that p210 is the sirolimus effector protein. © 1994 Academic Press, Inc.

Cite

CITATION STYLE

APA

Chen, Y., Chen, H., Rhoad, A. E., Warner, L., Caggiano, T. J., Failli, A., … Molnar-Kimber, K. L. (1994). A putative sirolimus (rapamycin) effector protein. Biochemical and Biophysical Research Communications, 203(1), 1–7. https://doi.org/10.1006/bbrc.1994.2140

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free